Exicure to Sell GPC-100 Program to Korea's GPCRT for ~$4.8M Cash
XCUR sits 39% above its 52-week low of $0.777 on elevated volume (2.6× avg).
Summary
Exicure agreed on November 4 to sell its GPC-100 (burixafor) program assets to Korea-based GPCRT Inc. for KRW 6.5 billion, about $4.8 million in cash. The price is roughly seven times the company's entire market value, and it comes as Exicure's Q2 10-Q showed cash down to $1.7M with a going concern warning and stockholders' equity below Nasdaq's minimum. Payment is staged: KRW 500 million already paid and credited, KRW 2.0 billion due by November 16, 2026, and KRW 4.0 billion at closing. GPCRT takes over the License and Collaboration Agreement obligations, including future milestones and royalties, and absorbs GPC-100 program costs from September 1, 2026, while Exicure keeps pre-September liabilities. Closing still needs third-party consents, a waiver and release from GPCR Therapeutics, Inc., and any required stockholder approval, so the cash is not yet certain. The sale is part of the strategic-alternatives review and follows the September 16 Nasdaq extension to December 2, 2026 to regain equity compliance.
Updates
· SEC 8-K — The KRW 6.5 billion price is payable as a KRW 500 million credited deposit, KRW 2.0 billion interim payment due by November 16, 2026, and KRW 4.0 billion at closing.
At the time of this announcement, XCUR was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.78 to $9.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.